These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

385 related items for PubMed ID: 30350418

  • 1. Clinical outcomes of fidaxomicin vs oral vancomycin in recurrent Clostridium difficile infection.
    Tieu JD, Williams RJ, Skrepnek GH, Gentry CA.
    J Clin Pharm Ther; 2019 Apr; 44(2):220-228. PubMed ID: 30350418
    [Abstract] [Full Text] [Related]

  • 2. Fidaxomicin versus oral vancomycin for severe Clostridium difficile infection: a retrospective cohort study.
    Gentry CA, Nguyen PK, Thind S, Kurdgelashvili G, Skrepnek GH, Williams RJ.
    Clin Microbiol Infect; 2019 Aug; 25(8):987-993. PubMed ID: 30583055
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Fidaxomicin versus metronidazole, vancomycin and their combination for initial episode, first recurrence and severe Clostridioides difficile infection - An observational cohort study.
    Polivkova S, Krutova M, Capek V, Sykorova B, Benes J.
    Int J Infect Dis; 2021 Feb; 103():226-233. PubMed ID: 33188906
    [Abstract] [Full Text] [Related]

  • 7. Outcomes With Fidaxomicin Therapy in Clostridium difficile Infection.
    Spiceland CM, Khanna S, Pardi DS.
    J Clin Gastroenterol; 2018 Feb; 52(2):151-154. PubMed ID: 28009682
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Cost-effectiveness analysis on the use of fidaxomicin and vancomycin to treat Clostridium difficile infection in France.
    Watt M, Dinh A, Le Monnier A, Tilleul P.
    J Med Econ; 2017 Jul; 20(7):678-686. PubMed ID: 28299963
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of fidaxomicin for the treatment of Clostridioides (Clostridium) difficile infection in a randomized, double-blind, comparative Phase III study in Japan.
    Mikamo H, Tateda K, Yanagihara K, Kusachi S, Takesue Y, Miki T, Oizumi Y, Gamo K, Hashimoto A, Toyoshima J, Kato K.
    J Infect Chemother; 2018 Sep; 24(9):744-752. PubMed ID: 29934056
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Efficacy of fidaxomicin versus vancomycin in the treatment of Clostridium difficile infection: A systematic meta-analysis.
    Zhao Z, Wu Y, Geng X, Yuan C, Fu Y, Yang G.
    Medicine (Baltimore); 2024 Aug 09; 103(32):e39213. PubMed ID: 39121324
    [Abstract] [Full Text] [Related]

  • 16. Fidaxomicin for treatment of Clostridium difficile infection in clinical practice: a prospective cohort study in a French University Hospital.
    Pichenot M, Héquette-Ruz R, Le Guern R, Grandbastien B, Charlet C, Wallet F, Schiettecatte S, Loeuillet F, Guery B, Galperine T.
    Infection; 2017 Aug 09; 45(4):425-431. PubMed ID: 28120176
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Successful treatment of simulated Clostridium difficile infection in a human gut model by fidaxomicin first line and after vancomycin or metronidazole failure.
    Chilton CH, Crowther GS, Freeman J, Todhunter SL, Nicholson S, Longshaw CM, Wilcox MH.
    J Antimicrob Chemother; 2014 Feb 09; 69(2):451-62. PubMed ID: 24003182
    [Abstract] [Full Text] [Related]

  • 19. Cost-effectiveness of three different strategies for the treatment of first recurrent Clostridium difficile infection diagnosed in a community setting.
    Lam SW, Neuner EA, Fraser TG, Delgado D, Chalfin DB.
    Infect Control Hosp Epidemiol; 2018 Aug 09; 39(8):924-930. PubMed ID: 29961435
    [Abstract] [Full Text] [Related]

  • 20. Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients aged ≥60 years (EXTEND): analysis of cost-effectiveness.
    Cornely OA, Watt M, McCrea C, Goldenberg SD, De Nigris E.
    J Antimicrob Chemother; 2018 Sep 01; 73(9):2529-2539. PubMed ID: 29800295
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.